AI assistant
Jazz Pharmaceuticals plc — Director's Dealing 2025
Mar 8, 2025
30751_dirs_2025-03-07_1dc7230c-0f72-45ff-b968-db1bf43b9545.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Jazz Pharmaceuticals plc (JAZZ)
CIK: 0001232524
Period of Report: 2025-03-05
Reporting Person: Iannone Robert (EVP, Global Head of R&D & CMO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2025-03-05 | Ordinary Shares | D | 5239 | $138.95 | Disposed | 89104 | Direct |
| 2025-03-07 | Ordinary Shares | S | 5532 | $138.21 | Disposed | 83572 | Direct |
| 2025-03-07 | Ordinary Shares | S | 1548 | $140.0 | Disposed | 82024 | Direct |
Footnotes
F1: Shares withheld to satisfy tax obligations arising out of vesting of a portion of previously granted restricted stock units.
F2: This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
F3: Reflects the sale of ordinary shares executed in multiple transactions at prices ranging from $138.19 to $138.23. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected.